The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: Implications for prostate cancer detection

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 3, 2011, Pages 501-508

  Wallner, Lauren P ^a,b   Morgenstern, Hal ^b   McGree, Michaela E ^c   Jacobson, Debra J ^c   St Sauver, Jennifer L ^c   Jacobsen, Steven J ^d   Sarma, Aruna V ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Mayo Clinic College of Medicine   (United States)

^d Kaiser Permanente Southern California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CAUCASIAN; CLINICAL EXAMINATION; DEMOGRAPHY; EDUCATION; FOLLOW UP; HEMODILUTION; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MARRIAGE; OBESITY; ORGAN SIZE; PLASMA VOLUME; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUESTIONNAIRE;

ADULT; AGED; BODY COMPOSITION; BODY MASS INDEX; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MINNESOTA; OBESITY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES;

EID: 79955768176     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-1006     Document Type: Article

References (31)

1. National Cancer Institute. Estimated new cases and deaths of prostate cancer[cited 2009; 7/06/10/]. Available from:http://www.cancer. gov/cancertopics/types/prostate.
2. Consedine NS, Morgenstern AH, Kudadjie-Gyamfi E, Magai C, Neugut AI. Prostate cancer screening behavior in men from seven ethnic groups: the fear factor. Cancer Epidemiol Biomarkers Prev 2006;15:228-37. (Pubitemid 43342168)
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
4. Laaksonen DE, Laukkanen JA, Niskanen L, Nyyssonen K, Rissanen TH, Voutilainen S, et al. Serum linoleic and total polyunsaturated fatty acids in relation to prostate and other cancers: a population-based cohort study. Int J Cancer 2004;111:444-50. (Pubitemid 38998828)
5. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303:235-41.
6. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007;29:88-97. (Pubitemid 47229642)
7. Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006;175:500-4. (Pubitemid 43067337)
8. Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 2007;16:70-6.
9. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007;298:2275-80. (Pubitemid 350146217)
10. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17:989-1003. (Pubitemid 44290764)
11. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007;109:675-84. (Pubitemid 46233228)
12. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006;15:1977-83. (Pubitemid 44664277)
13. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009;182:2232-41.
14. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996;155:595-600. (Pubitemid 26023551)
15. Jacobsen SJ, Guess HA, Panser L, Girman CJ, Chute CG, Oesterling JE, et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med 1993;2:729-35.
16. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-74.
17. Division of Nutrition, Physical Activity and Obesity. Centers for Disease Control and Prevention. Overweight and obesity[cited 2007; 7/ 06/18/]. Available from:http://www.cdc.gov/nccdphp/dnpa/obesity/.
18. Dubois D, Dubois EF. Nutrition metabolism classic: a formula to estimate the approximate surface-area if height and weight be known (reprinted from Arch Int Med 1916;17:863). Nutrition 1989;5:303-11.
19. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol 1984;247:F632-6.
20. Fowke JH, Motley SS, Cookson MS, Concepcion R, Chang SS, Wills ML, et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 2006;10:137-42.
21. Fowke JH, Signorello LB, Chang SS, Matthews CE, Buchowski MS, Cookson MS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African- American and Caucasian men. Cancer 2006;107:2361-7. (Pubitemid 44748518)
22. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005;103:1092-5. (Pubitemid 40270087)
23. Vickers AJ, Wolters T, Savage CJ, Cronin AM, O'Brien MF, Pettersson K, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009;56:753-60.
24. Grubb RL III, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2009;18:748-51.
25. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006;106:320-8. (Pubitemid 43100440)
26. Rundle AG, Neugut AI. Modeling the effects of obesity and weight gain on PSA velocity. Prostate 2009;69:1573-8.
27. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599-604. (Pubitemid 34793304)
28. Fowke JH, Motley SS, Wills M, Cookson MS, Concepcion RS, Eckstein CW, et al. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes Control 2007;18:375-84. (Pubitemid 46434798)
29. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004;22:446-53. (Pubitemid 41079773)
30. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004;22:439-45. (Pubitemid 41079772)
31. Gades NM, Jacobson DJ, McGree ME, Lieber MM, Roberts RO, Girman CJ, et al. Dropout in a longitudinal, cohort study of urologic disease in community men. BMC Med Res Methodol 2006;6:58.